Drugs / VIS410
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02045472 | Sep 2014 → May 2015 | influenza | Visterra, Inc. | Completed | No outcome recorded |
| Phase 23 trials · 2 met primary | ||||||
| Phase 2 | NCT03040141 | Jan → Nov 2018 | influenza | Visterra, Inc. | Completed | Met primary |
| Phase 2 | NCT02989194 | Jan → Oct 2017 | influenza | Visterra, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02468115 | May 2015 → Feb 2016 | influenza | Visterra, Inc. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIS410 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03040141 ↗ |
| Modality | Monoclonal antibody | “a broadly neutralizing monoclonal antibody (VIS410) against Influenza A” PMID 27077121 ↗ Feb 2016 |
| Route | Intravenous | “Single fixed IV dose of VIS410” NCT02468115 ↗ |